Press release
Osteoarthritis Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Key Takeaways from the Osteoarthritis Pipeline Report
* DelveInsight's Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
* The leading Osteoarthritis Companies working in the market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
* Promising Osteoarthritis Therapies in the various stages of development include E1K 1,200 /joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.
* April 2024:- Ensol Bioscience- The objective of this study is to evaluate the efficacy and safety of pain relief treatment on knee osteoarthritis when administered E1K or placebo in patients with knee osteoarthritis aged 40 to 70 to determine the optimal dose.
* April 2024:- Kolon TissueGene, Inc.- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee. This protocol is designed to assess the safety and efficacy of TG-C in treating symptoms of osteoarthritis of the knee and determining disease modifying effects of TG-C. This study is intended for the treatment of patients with KL Grade 2 and 3 osteoarthritis and OARSI JSN Grade 1 and 2.
Request a sample and discover the recent advances in Osteoarthritis treatment drugs @ Osteoarthritis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Osteoarthritis Overview
Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or "wear and tear" arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected. The main symptoms of osteoarthritis are pain and sometimes stiffness in the affected joints. The pain tends to be worse when the person move the joint or at the end of the day. Osteoarthritis is a leading cause of disability and source of societal cost in older adults. With an ageing and increasingly obese population, this syndrome is becoming even more prevalent than in previous decades.
Osteoarthritis Emerging Drugs Profile
* Lorecivivint: Biosplice Therapeutics
* CYP 004: Cynata Therapeutics
* JTA-004: Bone Therapeutics
* SMUP-IA-01: Medipost
* TTAX03: Tissue Tech
Find out more about Osteoarthritis treatment drugs @ Drugs for Osteoarthritis Treatment [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Osteoarthritis Therapeutics Assessment
There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.
DelveInsight's Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Learn more about the emerging Osteoarthritis pipeline therapies @ Osteoarthritis Clinical Trials [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Intravenous
* Subcutaneous
Osteoarthritis Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Osteoarthritis Companies
Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Dive deep into rich insights for new drugs for Osteoarthritis Treatment, visit @ Osteoarthritis Drugs [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Osteoarthritis Pipeline Report
* Coverage- Global
* Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
* Osteoarthritis Therapies- E1K 1,200 /joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.
For further information on the Osteoarthritis Pipeline Therapeutics, reach out @ Osteoarthritis Treatment Drugs [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Osteoarthritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Osteoarthritis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lorecivivint: Biosplice Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TTAX03: Tissue Tech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* GLPG-0555: Gilead Sciences
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Protego-PD: Plakous Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Osteoarthritis Key Companies
* Osteoarthritis Key Products
* Osteoarthritis- Unmet Needs
* Osteoarthritis- Market Drivers and Barriers
* Osteoarthritis- Future Perspectives and Conclusion
* Osteoarthritis Analyst Views
* Osteoarthritis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoarthritis-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoarthritis Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here
News-ID: 3491627 • Views: …
More Releases from ABNewswire
Small Business, Big Relief: CopperJoint Highlights Family Roots with New Compres …
As a small, family-run business based in the U.S., CopperJoint blends heart and science in every product. The new compression socks for women and men combine a modern look with doctor-approved compression and all-day support - ideal for healthcare workers, professionals, and active adults. "We may be small, but our impact is felt every time a customer says, 'I can move without pain again.'"
NASHVILLE, TN - September 21, 2025 -…
Kitchen Remodeling Enhances Both Functionality and Aesthetics in Homes
Modern upgrades focus on more than just visual appeal; they deliver functional improvements that make daily living easier.
Kitchen remodeling [https://neadesignandconstruction.com/#:~:text=01,Kitchen%20Remodeling] continues to shape the way homes are experienced across New Jersey, as families prioritize comfort, efficiency, and long-lasting design. Modern upgrades focus on more than just visual appeal; they deliver functional improvements that make daily living easier. With demand rising for reliable services, homeowners are turning to trusted providers like…
Home Remodeling Trends Position New Jersey as a Hub for Modern Design
Blending traditional craftsmanship with modern innovation, NEA Design and Construction continues to highlight how the state is becoming a leader in functional and stylish design transformations.
The demand for Home remodeling [https://neadesignandconstruction.com/#:~:text=Elevate%20Your-,Home,-Proudly%20serving%20homes] has seen remarkable growth in recent years, with many New Jersey property owners choosing to update and modernize their living spaces. Blending traditional craftsmanship with modern innovation, NEA Design and Construction continues to highlight how the state is becoming…
Local Infrastructure Strengthened Through General Contractor Expertise of NEA De …
Whether involving renovations, new builds, or large-scale developments, property owners require professionals who bring both expertise and reliability.
The demand for skilled general contractor [https://neadesignandconstruction.com/#:~:text=experience%20in%20the-,construction,-industry%2C%20our%20skilled] services has been steadily rising across New Jersey, where residential and commercial projects continue to shape local communities. Whether involving renovations, new builds, or large-scale developments, property owners require professionals who bring both expertise and reliability. Within this landscape, NEA Design and Construction has established itself…
More Releases for Osteoarthritis
Osteoarthritis Market Massive Growth opportunity Ahead
Introduction
Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation.
According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22…
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.…
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Osteoarthritis Treatment Market
Introduction
Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and…
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779
This latest report researches the industry structure, sales, revenue,…
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market.
What the Osteoarthritis Therapeutics Market Looks Like?
The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8…
